Proteomics Analysis for the Development of Personalized Medicines in Cardiovascular Diseases

Abstract

Through the thorough examination of protein expression and changes, proteomics has become a potent and revolutionary tool in personalised cardiovascular medicine, providing real-time insights into disease causes. Proteomics is particularly useful in complicated cardiovascular illnesses such myocardial infarction, heart failure, and atherosclerosis because, in contrast to genomics, it records dynamic physiological and pathological changes influenced by both hereditary and environmental variables. Together with the integration of multi-omics data and machine learning, technological advancements such as mass spectrometry, single-cell and spatial proteomics, and bioinformatics have made it easier to identify new biomarkers, enhance patient stratification, and direct customised treatment plans. Widespread clinical adoption is currently hampered by issues like technical variability, inadequate sensitivity for low-abundance proteins, regulatory barriers, and expensive prices, despite the potential for great success.  It is crucial to address these problems by standardising practices, collaborating across disciplines, and investing in infrastructure and training. Proteomics is positioned to become a key component of precision cardiology as the discipline develops and access to proteomic technologies increases, allowing for more individualised, predictive, and preventive methods of treating cardiovascular illness on a worldwide scale.